Fibroepithelial Tumors of the Breast Pathologic and Immunohistochemical Features and Molecular Mechanisms

被引:51
作者
Yang, Xiaofang
Kandil, Dina
Cosar, Ediz F.
Khan, Ashraf [1 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01605 USA
关键词
MALIGNANT PHYLLODES TUMORS; STROMAL CD10 EXPRESSION; BINDING PROTEIN IMP3; CORE NEEDLE-BIOPSY; MESSENGER-RNA; C-KIT; SURGICAL-TREATMENT; CELL CARCINOMA; GROWTH; CANCER;
D O I
10.5858/arpa.2012-0443-RA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-The 2 main prototypes of fibroepithelial tumors of the breast include fibroadenoma and phyllodes tumor (PT). Although both tumors share some overlapping histologic features, there are significant differences in their clinical behavior and management. Phyllodes tumors have been further divided into clinically relevant subtypes, and there is more than one classification scheme for PT currently in use, suggesting a lack of consistency within different practices. Accurate differentiation between fibroadenoma and PT, as well as the grading of PT, may sometimes be challenging on preoperative core needle biopsy. Some immunohistochemical markers have been suggested to aid in the pathologic classification of these lesions. Objective.-To discuss the salient histopathologic features of fibroepithelial tumors and review the molecular pathways proposed for the initiation, progression, and metastasis of PTs. Also, to provide an update on immunohistochemical markers that may be useful in their differential diagnosis and outline the practice and experience at our institution from a pathologic perspective. Data Sources.-Sources included published articles from peer-reviewed journals in PubMed (US National Library of Medicine). Conclusions.-Fibroepithelial tumor of the breast is a heterogenous group of lesions ranging from fibroadenoma at the benign end of the spectrum to malignant PT. There are overlapping histologic features among various subtypes, and transformation and progression to a more malignant phenotype may also occur. Given the significant clinical differences within various subtypes, accurate pathologic classification is important for appropriate management. Although some immunohistochemical markers may be useful in this differential diagnosis, histomorphology still remains the gold standard.
引用
收藏
页码:25 / 36
页数:12
相关论文
共 88 条
  • [1] Abe Hajime, 2004, Int J Clin Oncol, V9, P334
  • [2] Malignant transformation of breast fibroadenoma to malignant phyllodes tumor: long-term outcome of 36 malignant phyllodes tumors
    Abe, Makoto
    Miyata, Satoshi
    Nishimura, Seiichiro
    Iijima, Kotaro
    Makita, Masujiro
    Akiyama, Futoshi
    Iwase, Takuji
    [J]. BREAST CANCER, 2011, 18 (04) : 268 - 272
  • [3] Invasive ductal carcinoma within fibroadenoma and lung metastases
    Abu-Rahmeh, Zuhair
    Nseir, William
    Naroditzky, Inna
    [J]. INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2012, 5 : 19 - 21
  • [4] Agelopoulos K, 2007, CELL ONCOL, V29, P443
  • [5] The role of IGFBP-5 in mammary gland development and involution
    Allan, GJ
    Beattie, J
    Flint, DJ
    [J]. DOMESTIC ANIMAL ENDOCRINOLOGY, 2004, 27 (03) : 257 - 266
  • [6] AUGER M, 1989, ARCH PATHOL LAB MED, V113, P1231
  • [7] Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast
    Barrio, Andrea V.
    Clark, Bradly D.
    Goldberg, Jessica I.
    Hoque, Laura W.
    Bernik, Stephanie F.
    Flynn, Laurie W.
    Susnik, Barbara
    Giri, Dilip
    Polo, Kristen
    Patil, Sujata
    Van Zee, Kimberly J.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (10) : 2961 - 2970
  • [8] IMP3 expression in non-small, cell lung cancer
    Bellezza, Guido
    Cavaliere, Antonio
    Sidoni, Angelo
    [J]. HUMAN PATHOLOGY, 2009, 40 (08) : 1205 - 1206
  • [9] BERNSTEIN L, 1993, CANCER-AM CANCER SOC, V71, P3020, DOI 10.1002/1097-0142(19930515)71:10<3020::AID-CNCR2820711022>3.0.CO
  • [10] 2-G